The present study demonstrated that semaglutide treatment further enhanced the H/R-induced changes in autophagy activity, autophagosome levels and LC3-II/LC3-I ratio, suggesting a regulatory role of semaglutide in autophagy
Critics of GLP-1 therapies often portray those who use these medications as opting for an easy way out to achieve thinness, perpetuating longstanding biases like those historically associated with bariatric surgery (Heitmann, 2025)
What We Know So Far Body composition research published through 2025 and 2026 has established several findings that are directly relevant to older adults on GLP-1 therapy: Up to 40% of total weight lost on high-efficacy GLP-1 medications is lean body mass rather than fat, according to body composition analyses cited across multiple clinical reviews
However, studies evaluating the role of omega-3 PUFA-based nutraceuticals in the setting of thyroid disorders, reached inconclusive results [133]
Monitoring: All patients are closely monitored by our providers for safety and effectiveness
